Compare Boston Scientific Corporation (BSX) vs New York Times Co (NYT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs New York Times Co — how do they compare? Boston Scientific Corporation trades at $51.12 (market cap $74.19B), while New York Times Co trades at $64.19 (market cap $10.28B). The key difference: Boston Scientific Corporation is far larger — about 7.2× New York Times Co's market cap, and New York Times Co pays a 1.44% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| BSX | NYT | |
|---|---|---|
Market Cap | $74.19B | $10.28B |
Sector | Health | Media |
52-Week High | $108.14 | $85.86 |
52-Week Low | $42.63 | $54.66 |
Enterprise Value | $86.27B | $9.67B |
Dividend Yield | — | 1.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BSX trades at $50.46, up 2.33% today, with strong earnings beats in recent quarters and a bullish technical trend. Revenue grew to $20.07B in 2025, with net income margin expanding to 17.5%. The stock shows robust institutional support and insider buying, while facing near-term headwinds from competitive pressures in key segments like WATCHMAN.
Outlook remains positive with 86% analyst buy ratings and a $67.21 consensus price target, implying 33% upside. Risks include guidance cuts and market share losses, but solid cash flow and valuation metrics support long-term growth potential for patient investors.
The New York Times Company (NYT) trades at $64.80, up 1.98% today, with a bearish technical signal despite recent earnings beats. Fundamentals show strong revenue growth to $2.82 billion in 2025 and a net income margin of 13.19%, though digital subscriber growth concerns have pressured the stock. The current P/E ratio is 26.55, above industry averages, reflecting its premium valuation.
The outlook is mixed; solid profitability and a consensus price target of $77.50 suggest upside, but slowing subscriber additions and high valuation pose risks. Investor sentiment is cautious due to recent price weakness, with analysts predominantly holding a 'Hold' rating, indicating a wait-and-see approach for near-term catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About New York Times Co
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.
Read more on NYT →
